EMA Authorised: Visudyne (verteporfin) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

EMA confirms authorisation of Visudyne (verteporfin) by CHEPLAPHARM Arzneimittel GmbH for indications related to degenerative myopia and macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Degenerative Myopia

Drugs mentioned

• Visudyne (verteporfin)

Snippet

Status: Authorised. Therapeutic area: Myopia, Degenerative;Macular Degeneration. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 02/09/2020